Corporate Profile
Founded in 1992, Conceptus®, Inc. is dedicated to the revolutionary design, development, and marketing of innovative solutions to advance women's health. We developed the market leading Essure® procedure, the first-ever non-surgical permanent birth control method. After a decade on the market, Essure remains the most effective form of permanent birth control* available worldwide. We are committed to making Essure the standard of care for permanent birth control, and we intend to provide additional women's health solutions for both patients and physicians.
*based on four years of clinical study data
Shareholder information
Exchange:
Conceptus, Inc.'s common stock trades on The NASDAQ Global Select MarketSM under the symbol CPTS.
Transfer agent:
BNY Mellon Shareowner Services
P.O. Box 358015
Pittsburgh, PA 15252-8015
(877) 258-2911 (phone)
www.bnymellon.com/shareowner/equityaccess
View all » 
Recent Releases
Jan 9, 2012
Conceptus(R) Announces That Hologic's Motion for New Trial in Patent Infringement Case is Denied
Jan 9, 2012
Conceptus(R) to Discontinue GYNECARE THERMACHOICE(R) Promotion and Restructure U.S. Sales Organization
View all »Events & Presentations
Nov 29, 2011
23rd Annual Piper Jaffray Health Care Conference
Listen to webcast